Pages that link to "Q26995499"
Jump to navigation
Jump to search
The following pages link to Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience (Q26995499):
Displayed 26 items.
- The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics (Q26738677) (← links)
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports (Q28553328) (← links)
- Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance (Q36125878) (← links)
- Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities (Q37369239) (← links)
- Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential (Q38414485) (← links)
- Immune checkpoint inhibitors: a new frontier in bladder cancer (Q38612706) (← links)
- Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies (Q38636711) (← links)
- Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data (Q38648615) (← links)
- Prospects for the use of ipilimumab in treating advanced prostate cancer (Q38677420) (← links)
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer (Q38710357) (← links)
- Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review (Q38783026) (← links)
- Immune Checkpoint Therapies in Prostate Cancer (Q38816839) (← links)
- Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer (Q39085984) (← links)
- Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis (Q39148284) (← links)
- Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. (Q46112903) (← links)
- Adverse Events in Cancer Immunotherapy (Q46884498) (← links)
- Ipilimumab for the treatment of metastatic prostate cancer (Q47225399) (← links)
- Immunotargeting and personalized therapies in genitourinary cancers (Q48133624) (← links)
- [Immunotherapy for the treatment of prostate cancer-a comeback?] (Q57811796) (← links)
- Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma (Q88312688) (← links)
- Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy (Q89097028) (← links)
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities (Q90701915) (← links)
- Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer (Q90834120) (← links)
- Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies (Q92349905) (← links)
- Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: Three case reports and literature review (Q92980431) (← links)
- Progress in Neoantigen Targeted Cancer Immunotherapies (Q98771735) (← links)